CN103140227B - 制备微管蛋白细胞溶素的方法 - Google Patents

制备微管蛋白细胞溶素的方法 Download PDF

Info

Publication number
CN103140227B
CN103140227B CN201180048479.0A CN201180048479A CN103140227B CN 103140227 B CN103140227 B CN 103140227B CN 201180048479 A CN201180048479 A CN 201180048479A CN 103140227 B CN103140227 B CN 103140227B
Authority
CN
China
Prior art keywords
compound
formula
alkyl
optionally substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180048479.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103140227A (zh
Inventor
I.R.弗拉霍夫
M.格罗亚宁
P.J.克莱恩德尔
H.K.R.桑塔拉普拉姆
F.尤
Y.王
L.许
K.M.斯坦福德
A.里特
C.P.利蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN103140227A publication Critical patent/CN103140227A/zh
Application granted granted Critical
Publication of CN103140227B publication Critical patent/CN103140227B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201180048479.0A 2010-08-06 2011-08-05 制备微管蛋白细胞溶素的方法 Expired - Fee Related CN103140227B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
US61/371433 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Publications (2)

Publication Number Publication Date
CN103140227A CN103140227A (zh) 2013-06-05
CN103140227B true CN103140227B (zh) 2016-01-20

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180048479.0A Expired - Fee Related CN103140227B (zh) 2010-08-06 2011-08-05 制备微管蛋白细胞溶素的方法

Country Status (12)

Country Link
US (3) US8889880B2 (cg-RX-API-DMAC7.html)
EP (1) EP2600866A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013535220A (cg-RX-API-DMAC7.html)
KR (1) KR20130096712A (cg-RX-API-DMAC7.html)
CN (1) CN103140227B (cg-RX-API-DMAC7.html)
AU (1) AU2011285532B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013003004A2 (cg-RX-API-DMAC7.html)
CA (1) CA2807511A1 (cg-RX-API-DMAC7.html)
EA (1) EA025471B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013001402A (cg-RX-API-DMAC7.html)
SG (1) SG187728A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012019123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
EA025471B1 (ru) 2010-08-06 2016-12-30 Эндосайт, Инк. Способы получения тубулизинов
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (cg-RX-API-DMAC7.html) 2012-10-16 2015-10-16 Endocyte Inc
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140249315A1 (en) * 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
AU2015213106B2 (en) * 2014-01-28 2019-07-25 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
EA201791896A1 (ru) * 2015-02-25 2018-02-28 Уильям Марш Райс Юниверсити Дезацетокситубулизин н и его аналоги
SG11201803068YA (en) 2015-11-10 2018-05-30 Medimmune Llc Binding molecules specific for asct2 and uses thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
IL312451A (en) 2017-08-01 2024-06-01 Medimmune Llc Bcma monoclonal antibody-drug conjugate
WO2019108685A1 (en) 2017-11-29 2019-06-06 William March Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
KR20230084497A (ko) 2020-09-11 2023-06-13 메디뮨 리미티드 치료용 b7-h4 결합 분자
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
JP2024544520A (ja) 2021-11-10 2024-12-03 アストラゼネカ・アクチエボラーグ 抗体分子及び複合体
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
AU2023229884A1 (en) 2022-03-09 2024-10-10 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
EP4543920A1 (en) 2022-06-27 2025-04-30 Astrazeneca AB Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2024220870A1 (en) 2023-02-16 2025-10-02 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
EP2517729A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EA025471B1 (ru) 2010-08-06 2016-12-30 Эндосайт, Инк. Способы получения тубулизинов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Total Synthesis of Tubulysin D;Hillary M. Peltier, et al;《J. AM. CHEM. SOC.》;20061201;第128卷;16018-16019 *

Also Published As

Publication number Publication date
AU2011285532A1 (en) 2013-02-21
JP2013535220A (ja) 2013-09-12
KR20130096712A (ko) 2013-08-30
EA201390203A1 (ru) 2013-08-30
US9273091B2 (en) 2016-03-01
SG187728A1 (en) 2013-03-28
BR112013003004A2 (pt) 2016-06-14
US8889880B2 (en) 2014-11-18
EP2600866A4 (en) 2013-12-11
CN103140227A (zh) 2013-06-05
WO2012019123A1 (en) 2012-02-09
CA2807511A1 (en) 2012-02-09
HK1185558A1 (zh) 2014-02-21
US20150225447A1 (en) 2015-08-13
AU2011285532B2 (en) 2015-09-10
EP2600866A1 (en) 2013-06-12
US20130137139A1 (en) 2013-05-30
EA025471B1 (ru) 2016-12-30
MX2013001402A (es) 2013-08-29
US9499849B2 (en) 2016-11-22
US20160177363A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
CN103140227B (zh) 制备微管蛋白细胞溶素的方法
US9771391B2 (en) Process for preparing tubulysins
EP2831059B1 (en) Processes for preparing tubulysin derivatives and conjugates thereof
Dahiya Synthesis, characterization and antimicrobial studies on some newer imidazole analogs
CN110117293B (zh) 多氟取代的Largazole类似物、其制备方法和用途
JP2006527173A (ja) コルヒチン類似体
US7365055B2 (en) Derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses
HK1185558B (en) Processes for preparing tubulysins
US5151521A (en) 1-aminoethyl phosphonic acid derivatives
JPS59199693A (ja) インドリルグリシルセフアロスポリン誘導体
JP6570034B2 (ja) 新規なグルタミン酸誘導体およびその用途
AU2013203491A1 (en) Processes for preparing tubulysins
KR970004044B1 (ko) 약물동력학적으로 개선된 세팔로스포린 유도체, 그의 제조방법, 그를 함유하는 약제학적 조성물 및 합성 중간체
KR100450607B1 (ko) 가라민 유도체의 제조방법
JP2023084946A (ja) 生理活性を有する新規化合物
WO2025169980A1 (ja) テストステロンの産生／分泌を調節するための環状ペプチド誘導体組成物
WO1999021867A1 (fr) Derives d'erythromycine a
JPWO1999021867A1 (ja) エリスロマイシンａ誘導体
IT8422036A1 (it) Derivati dell'1,3-diossano, procedimento per la loro preparazione composizioni farmaceutiche

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185558

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1185558

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20170805

CF01 Termination of patent right due to non-payment of annual fee